STTK - shattucklabs.com Debt to Book Capitalization Ratio

Graphic logo of Shattuck Labs (STTK)

Shattuck Labs, Inc. (STTK) develops cutting-edge platforms for immune activation in the fight against cancer. This chart of the total debt-to-book capitalization ratio shows that the value remains at 0.01. Patents for bifunctional proteins guarantee a long-term monopoly, creating a stable cash cow. However, business success relies on the results of clinical trials for oncology drugs and strict control of R&D expenditures.

STTK (Shattuck Labs) Debt to Book Value history from 07/04/2022 to 10/28/2026
Core merchandise of shattucklabs.com

This indicator compares total liabilities to equity to assess financial leverage and solvency. The metric determines the balance between default risk and the efficiency of borrowed funds. The historical trend of the debt-to-equity ratio reflects the financial stability of Shattuck Labs, Inc. (STTK) while conducting costly oncology research. Institutional investor confidence in Taylor Schreiber's team allows for the optimization of this ratio. The stability of this indicator confirms the reliability of the biotech's development strategy.

Who Shattuck Labs, Inc. competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Zenas Bio - Debts to Book Value|Debt to Book Capitalization Ratio IMNM (Immunome Corp)|GOSS - Debts to Net Assets|Debts to Book Capitalization KalVista Pharmaceuticals KALV|septerna.com (SEPN) - Debt to Net Assets Ratio|PVLA (Pieris Pharmaceuticals, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization Savara Inc (SVRA)|Debt to Book Value Rigel Pharmaceuticals Inc|Debt to Book Capital AnaptysBio Inc. ANAB|Debt to Book Value Astria Therapeutics (ATXS)|ENGN - Debt to Book Capital|RAPT Therapeutics, Inc. - Debt to Book Value|JBIO - Debts to Book Capitalization|ACRS (Aclaris) - Debts to Book Capitalization|KYTX (Kyverna Therapeutics, Inc) - Debt to Book Value|TLSA (Tiziana Life Sciences) - Debt to Book Capitalization Ratio|Debts to Book Capitalization cabalettabio.com (CABA)|Ventyx Biosciences, Inc. (VTYX) - Debt to Book Value|Debt to Net Assets Ratio THTX (Theratechnologies, Inc.)|Debt to Book Capitalization Ratio Avalo Therapeutics Inc. AVTX|Debt to Book Capitalization Ratio Eledon Pharmaceuticals, Inc ELDN|Agenus - Debts to Book Capitalization|CLYM - Debts to Book Capitalization|Zura Bio Limited (ZURA) - Debts to Book Capitalization|ATYR (aTyr Pharma Inc) - Debt to Book Capitalization Ratio|ADAG: Debt to Book Capitalization Ratio|Debts to Net Assets Ikena Oncology, Inc. (IMA)|Equillium, Inc. (EQ) - Debt to Book Value|Debt to Net Assets Ratio connectbiopharm.com (CNTB)|Debts to Book Capitalization IMUX|Atara Biotherapeutics, Inc. - Debts to Net Assets|InflaRx GmbH (IFRX) - Debt to Book Capitalization Ratio|XFOR - Debt to Book Value Ratio|ACET (adicetbio.com) - Debts to Book Capitalization|Debt to Book Value Celularity|INMB: Debt to Book Value|Debts to Net Assets BRNS|KZR (Kezar Life Sciences, Inc) - Debt to Book Capitalization Ratio|Debts to Net Assets SAB Biotherapeutics Inc SABS|Debt to Book Value Akari Therapeutics (AKTX)|ENLV - Debt to Book Capital|Debt to Book Value Q32 Bio Corp QTTB|GOVX: Debt to Book Capital|EDSA: Debt to Book Capitalization Ratio|IBIO (iBio Corporation) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Carisma Therapeutics Inc CARM|Debts to Book Capitalization Ratio xtlbio.com|Bolt Biotherapeutics (BOLT) - Debts to Book Capitalization|Debt to Net Assets Ratio hcwbiologics.com (HCWB)|Debts to Book Capitalization APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. - Debts to Book Capitalization|Debt to Book Capitalization Ratio Aditxt Corp (ADTX)|GRI: Debt to Net Assets Ratio|XRTX (XORTX Therapeutics) - Debt to Book Capitalization Ratio|Vyome Holdings Inc. (HIND) - Debt to Book Value|REVB (Revelation Bio) - Debts to Book Capitalization|Debts to Book Capitalization Indaptus Corp (INDP)|Scinai Immunotherapeutics (SCNI) - Debt to Book Value|Debt to Net Assets Ratio calcimedica.com (CALI)|Debts to Book Capitalization AFMD|Allakos Inc - Debts to Net Assets|HOOK: Debt to Book Capitalization Ratio|IGMS: Debt to Book Value|ITOS (iTeos Therapeutics) - Debt to Book Capitalization Ratio|Debt to Book Value oceanbiomedical.com|TCBP (TC BioPharm) - Debt to Book Value|Debts to Book Capitalization THRD